Vaccine maker Adimmune Corp (國光生技) plans to conduct phase I clinical trials of its COVID-19 candidate vaccine next month to assess its safety, the firm said yesterday.
Adimmune expects to receive approval from the Food and Drug Administration (FDA) later this month to start trials, as the review has been going smoothly so far, Adimmune spokesman Pan Fei (潘飛) told the Taipei Times by telephone.
The vaccine provider would cooperate with National Taiwan University Hospital (NTUH) for the trials, Pan said.
The company plans to enroll 60 to 80 healthy adult participants, who would be divided into several groups and receive vaccines at different doses, to see if the experimental vaccine is safe, Pan said.
“We will monitor if there are any severe side effects to the participants and if they produce coronavirus antibodies. Based on the results of phase I trials, we will select two dose levels that show the most promise to continue with phase II clinical trials,” Pan said.
Although Minister of Health and Welfare Chen Shih-chung (陳時中) last week said that the government would allow biotechnology firms to skip phase III clinical trials of their vaccine candidates to accelerate vaccine development, Adimmune would not eschew the final phase of human trials, Pan said.
“We are considering combining phase II and phase III trials into a phase II/III design to save time and reduce the total number of test participants,” he said.
The firm still needs to discuss with the regulator the protocol for a phase II/III trial, including clinical endpoints and the number of enrolled participants, he added.
Adimmune, the nation’s largest flu vaccine provider, is a frontrunner in the local race to develop a COVID-19 vaccine, as it was the first to apply to the FDA to conduct human trials.
Its vaccine candidate, developed using the novel coronavirus’ genetic sequence and the firm’s recombinant protein technology, in an animal test in April caused laboratory mice to produce antibodies that could inhibit the growth of the coronavirus, company data showed.
The firm’s achievements have been rewarded by investors, with its stock price rising from NT$36.35 on May 6 — when it announced the results of its animal test — to NT$75.6 at the close of Taipei trading yesterday.
However, the company did not take advantage of its high stock price to raise capital, as it did not issue new common shares, but took out a NT$4.2 billion (US$142 million) syndicated loan from nine local banks to fuel research, new factories and international development.
“Taking the syndicated loan did not increase our financial burden thanks to lower interest rates while we did not want to expand the number of shares in the short term due to concerns over stock dilution,” Pan said.
Last week, Medigen Vaccine Biologics Corp (高端疫苗) applied to the FDA to run phase I human trials for its spike protein-based vaccine candidate, becoming second in the local race to produce a COVID-19 vaccine, company data showed.
Separately yesterday, Golden Biotechnology Corp (GBC, 國鼎生物科技) announced that it has gained approval from the US Food and Drug Administration to conduct phase II human trials for its small molecule drug, Antroquinonol (Hocena), as COVID-19 treatment, it said in a filing with the Taipei Exchange.
The drug, originally developed to treat pancreatic cancer, has proven safe in its phase I human trial in the US, the firm said.
TECH BOOST: New TSMC wafer fabs in Arizona are to dramatically improve US advanced chip production, a report by market research firm TrendForce said With Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) pouring large funds into Arizona, the US is expected to see an improvement in its status to become the second-largest maker of advanced semiconductors in 2027, Taipei-based market researcher TrendForce Corp (集邦科技) said in a report last week. TrendForce estimates the US would account for a 21 percent share in the global advanced integrated circuit (IC) production market by 2027, sharply up from the current 9 percent, as TSMC is investing US$65 billion to build three wafer fabs in Arizona, the report said. TrendForce defined the advanced chipmaking processes as the 7-nanometer process or more
China’s Huawei Technologies Co (華為) plans to start mass-producing its most advanced artificial intelligence (AI) chip in the first quarter of next year, even as it struggles to make enough chips due to US restrictions, two people familiar with the matter said. The telecoms conglomerate has sent samples of the Ascend 910C — its newest chip, meant to rival those made by US chipmaker Nvidia Corp — to some technology firms and started taking orders, the sources told Reuters. The 910C is being made by top Chinese contract chipmaker Semiconductor Manufacturing International Corp (SMIC, 中芯) on its N+2 process, but a lack
Who would not want a social media audience that grows without new content? During the three years she paused production of her short do-it-yourself (DIY) farmer’s lifestyle videos, Chinese vlogger Li Ziqi (李子柒), 34, has seen her YouTube subscribers increase to 20.2 million from about 14 million. While YouTube is banned in China, her fan base there — although not the size of YouTube’s MrBeast, who has 330 million subscribers — is close to 100 million across the country’s social media platforms Douyin (抖音), Sina Weibo (新浪微博) and Xiaohongshu (小紅書). When Li finally released new videos last week — ending what has
OPEN SCIENCE: International collaboration on math and science will persevere even if the incoming Trump administration imposes strict controls, Nvidia’s CEO said Nvidia Corp CEO Jensen Huang (黃仁勳) said on Saturday that global cooperation in technology would continue even if the incoming US administration imposes stricter export controls on advanced computing products. US president-elect Donald Trump, in his first term in office, imposed restrictions on the sale of US technology to China citing national security — a policy continued under US President Joe Biden. The curbs forced Nvidia, the world’s leading maker of chips used for artificial intelligence (AI) applications, to change its product lineup in China. The US chipmaking giant last week reported record-high quarterly revenue on the back of strong AI chip
RSS